The growth inhibitory effects of the Src inhibitor, dasatinib, in combination with the MEK1/2 inhibitor trametinib were analyzed in 23 thyroid cancer cell lines expressing clinically relevant mutations (BRAF, RAS, RET/PTC1). Here, BRAF is linked to thyroid cancer.